Grade 3 or more TEAEs, serious TEAEs, and TEAEs of interest for BTK inhibitors in the LTE1 study
| . | Patients in LTE1 (N = 47) . | |
|---|---|---|
| Grade ≥3 TEAEs in ≥2 patients (5%), by preferred term, n (%) | ||
| Anemia | 2 (4.3) | |
| COVID-19/COVID-19 pneumonia grouped | 3 (6.4) | |
| Neutropenia/neutrophil count decreased grouped | 2 (4.3) | |
| Serious TEAEs in ≥2 patients (5%), by preferred term: pericarditis, n (%) | 2 (4.3) | |
| TEAEs of interest for BTK inhibitors, n (%) | Any grade | Grade ≥3 |
| Infections | 22 (46.8) | 3 (6.4) |
| Hypertension | 1 (2.1) | 1 (2.1) |
| Hemorrhage | 6 (12.8) | 1 (2.1) |
| Neutropenia, grouped term | 5 (10.6) | 2 (4.3) |
| Anemia, grouped term | 4 (8.5) | 2 (4.3) |
| Second primary malignancies: skin cancers | 4 (8.5) | 0 |
| Second primary malignancies: nonskin cancers | 1 (2.1) | 0 |
| Thrombocytopenia, grouped term | 1 (2.1) | 0 |
| Atrial fibrillation/flutter | 1 (2.1) | 0 |
| . | Patients in LTE1 (N = 47) . | |
|---|---|---|
| Grade ≥3 TEAEs in ≥2 patients (5%), by preferred term, n (%) | ||
| Anemia | 2 (4.3) | |
| COVID-19/COVID-19 pneumonia grouped | 3 (6.4) | |
| Neutropenia/neutrophil count decreased grouped | 2 (4.3) | |
| Serious TEAEs in ≥2 patients (5%), by preferred term: pericarditis, n (%) | 2 (4.3) | |
| TEAEs of interest for BTK inhibitors, n (%) | Any grade | Grade ≥3 |
| Infections | 22 (46.8) | 3 (6.4) |
| Hypertension | 1 (2.1) | 1 (2.1) |
| Hemorrhage | 6 (12.8) | 1 (2.1) |
| Neutropenia, grouped term | 5 (10.6) | 2 (4.3) |
| Anemia, grouped term | 4 (8.5) | 2 (4.3) |
| Second primary malignancies: skin cancers | 4 (8.5) | 0 |
| Second primary malignancies: nonskin cancers | 1 (2.1) | 0 |
| Thrombocytopenia, grouped term | 1 (2.1) | 0 |
| Atrial fibrillation/flutter | 1 (2.1) | 0 |